Endomyocardial monophasic action potential for early detection of myocardium pathology
AssigneeThe Regents of the University of California
InventorsLuyi Sen, Guanggen Cui
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Regents of the University of California
InventorsLuyi Sen, Guanggen Cui
Estimating the term…
A catheter-delivered electrode array is used to three dimensionally map the endomyocardial monophasic action potential (MAP). The catheter is used in a method for endomyocardial MAP mapping and for establishing diagnostic criteria for the cardiac myocyte injury. During allograft rejection, conduction impairment occurs within the atrial myocardium. Abnormalities of the terminal force of the P wave in Lead V1 (ptfV1) and dispersion of corrected atrial repolarization (Ta-TcD) represent interatrial conduction defects that accompanies the rejection process. Three dimensional endomyocardium monophasic action potential mappings are used to directly monitor the pathophysiological changes in cardiac myocytes. Changes in amplitude, duration and morphology of the action potential were recorded and used to detect the early rejection of the transplant organ with high sensitivity and specificity. Using this MAP-mapping system, the area of myocardium injury induced by a coronary artery occlusion or by ablation can be pin pointed.
An apparatus for three-dimensional interior mapping of endomyocardial monophasic action potential (MAP) of endomycardial tissue comprising:
A method of determining the myocardium injury/electrical-pathophysiology of cardiac myocytes comprising:
Dependencies are inferred from the claim text.